Form 8-K EXELIXIS, INC. For: Dec 16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM |
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 16, 2021
(Exact name of registrant as specified in its charter) |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(650 ) 837-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 16, 2021, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Exelixis, Inc. ("Exelixis"), the Board increased the size of the Board to 12 members and appointed Jacky Wright to the Board to fill the newly created vacancy. Ms. Wright was also appointed as a member of the Nominating and Corporate Governance Committee of the Board and as a member of the Risk Committee of the Board.
As a non-employee director, Ms. Wright will be entitled to receive the standard cash and equity compensation for non-employee directors described under the caption “Compensation of Directors” in Exelixis’ 2021 proxy statement, filed with the Securities and Exchange Commission on April 15, 2021.
In addition to the indemnification provided for directors in Exelixis' Bylaws, Exelixis intends to enter into its standard form of Indemnification Agreement with Ms. Wright, previously filed as Exhibit 10.1 to Exelixis’ Registration Statement on Form S-1/A (File No. 333-96335), filed with the Securities and Exchange Commission on March 17, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXELIXIS, INC. | |||||||||||
December 17, 2021 | /s/ JEFFREY J. HESSEKIEL | ||||||||||
Date | Jeffrey J. Hessekiel | ||||||||||
Executive Vice President and General Counsel |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Former Swedish Country Manager returns to Konsolidator as a Sales Partner
- The Pillar 2 requirement for Aktia decreases by 0.25 percentage points to 1.00%
- CURE Media Group and Oncology Nursing News® announce Meaghan Mooney, B.S.N., RN, OCN, as the winner of the 2024 Extraordinary Healer® Award
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!